Zweig-DiMenna Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Zweig-DiMenna Associates’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-54,100	Closed	-$11.6M	–	232
2021 Q1	$11.6M	Buy	+54,100	New	+$11.9M	0.81%	50
2016 Q1	–	Sell	-151,150	Closed	-$19M	–	281
2015 Q4	$19M	Sell	151,150 -187,291	-55%	-$22.6M	0.95%	35
2015 Q3	$35.2M	Buy	338,441 +311,441	+1,153%	+$40M	1.53%	13
2015 Q2	$3.33M	Sell	27,000 -142,387	-84%	-$17.9M	0.18%	101
2015 Q1	$20M	Buy	169,387 +7,180	+4%	+$860K	0.84%	38
2014 Q4	$19.3M	Buy	162,207 +81,280	+100%	+$9.15M	0.83%	43
2014 Q3	$9.09M	Buy	80,927 +33,427	+70%	+$3.18M	0.4%	83
2014 Q2	$4.5M	Buy	+47,500	New	+$3.33M	0.21%	109
2013 Q3	–	Sell	-98,790	Closed	-$7.91M	–	272
2013 Q2	$7.91M	Buy	+98,790	New	+$7.28M	0.32%	102

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Zweig-DiMenna Associates's VRTX Position: Q2 2021 in Review

Zweig-DiMenna Associates sold out of Vertex Pharmaceuticals (VRTX) in Q2 2021, closing a stake of 54,100 shares — an estimated $11.6M sold.

Zweig-DiMenna Associates first reported a position in VRTX in Q2 2013 and held it in 9 quarters. The position peaked at $35.2M in Q3 2015. 978 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

Zweig-DiMenna Associates reported no remaining Vertex Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Zweig-DiMenna Associates sold 54,100 Vertex Pharmaceuticals shares in Q2 2021, an estimated $11.6M.
Zweig-DiMenna Associates first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 9 quarters.
Zweig-DiMenna Associates's Vertex Pharmaceuticals position peaked at $35.2M in Q3 2015.
978 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on Zweig-DiMenna Associates's 13F filing for Q2 2021, filed 29 Jul 2021.